Previous close | 42.66 |
Open | 42.76 |
Bid | 42.76 x 100 |
Ask | 43.14 x 100 |
Day's range | 42.08 - 43.19 |
52-week range | 27.99 - 50.99 |
Volume | |
Avg. volume | 429,937 |
Market cap | 3.244B |
Beta (5Y monthly) | 1.17 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.73 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 58.10 |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event. Company Fireside Chat Presentation Details: Date:Tuesday, March 19, 2024 Time:12:30-12:55 PM Eastern Time Webcast:Register here Presenters: Sherry Aulin, Chief Financial Officer Chris Von Seggern, Chief Commercial Officer A live webcast of the company presen
Xenon Pharmaceuticals Inc (NASDAQ:XENE), a clinical-stage biopharmaceutical company, focuses on developing therapeutics to improve the lives of patients with neurological disorders.